Osmotica Pharmaceuticals plc Receives FDA Approval for Upneeq™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for Acquired Blepharoptosis (Droopy Eyelid) in Adults
09 juil. 2020 06h50 HE
|
Osmotica Holdings US LLC
-- First and only FDA-approved pharmacologic treatment for acquired blepharoptosis -- -- Company to host Investor Call at 10:00 a.m. ET today to discuss approval, key elements of the clinical data...
Osmotica Pharmaceuticals US LLC Submits Amended NDA for Arbaclofen Extended Release Tablets to U.S. Food and Drug Administration
30 juin 2020 06h50 HE
|
Osmotica Holdings US LLC
-- Submission based on world’s largest database of patients treated for spasticity associated with Multiple Sclerosis -- -- Demonstrated efficacy, tolerability and one-year safety results on 80...
Osmotica Pharmaceuticals plc to Present at Jefferies Virtual Optical Health Summit
16 juin 2020 16h30 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that...
Osmotica Pharmaceuticals plc to Present at 2020 Jefferies Virtual Healthcare Conference
26 mai 2020 16h30 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that...
Osmotica Pharmaceuticals plc to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
13 mai 2020 17h08 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., May 13, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that...
Osmotica Pharmaceuticals plc Reports First Quarter 2020 Results and Provides Business Updates
12 mai 2020 16h05 HE
|
Osmotica Holdings US LLC
First quarter 2020 total revenue of $48.6 million On track to achieve major 2020 milestones BRIDGEWATER, N.J., May 12, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT)...
Osmotica Pharmaceuticals plc to Provide First Quarter 2020 Business and Financial Update on May 12, 2020
08 mai 2020 13h30 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., May 08, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the...
Osmotica Pharmaceuticals plc Reports Fourth Quarter and Full Year 2019 Results and Provides Business Updates
18 mars 2020 16h05 HE
|
Osmotica Holdings US LLC
Fourth quarter and full year 2019 total revenue of $59.9 million and $240.0 million, respectively New Drug Application accepted by FDA for RVL-1201 (oxymetazoline hydrochloride ophthalmic solution,...
Osmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2019 Business and Financial Update on March 18, 2020
12 mars 2020 18h00 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., March 12, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that...
Osmotica to Present at Barclays Global Healthcare Conference 2020
03 mars 2020 06h50 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., March 03, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that...